Biofrontera AG
Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carci… Read more
Biofrontera AG (B8FK) - Total Assets
Latest total assets as of September 2025: €19.81 Million EUR
Based on the latest financial reports, Biofrontera AG (B8FK) holds total assets worth €19.81 Million EUR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Biofrontera AG - Total Assets Trend (2009–2024)
This chart illustrates how Biofrontera AG’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Biofrontera AG - Asset Composition Analysis
Current Asset Composition (December 2024)
Biofrontera AG's total assets of €19.81 Million consist of 54.8% current assets and 45.2% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 10.5% |
| Accounts Receivable | €6.45 Million | 21.8% |
| Inventory | €4.44 Million | 15.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €1.00 Million | 3.4% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2009–2024)
This chart illustrates how Biofrontera AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biofrontera AG's current assets represent 54.8% of total assets in 2024, an increase from 47.8% in 2009.
- Cash Position: Cash and equivalents constituted 10.5% of total assets in 2024, down from 41.8% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, a decrease from 41.0% in 2009.
- Asset Diversification: The largest asset category is accounts receivable at 21.8% of total assets.
Biofrontera AG Competitors by Total Assets
Key competitors of Biofrontera AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biostar Pharmaceuticals Inc
PINK:BSPM
|
USA | $41.43 Million |
|
High Sierra Technologies Inc
PINK:HSTI
|
USA | $10.70K |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
Biofrontera AG - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Biofrontera AG generates 0.73x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Biofrontera AG is currently not profitable relative to its asset base.
Biofrontera AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.91 | 2.04 | 2.69 |
| Quick Ratio | 2.09 | 1.20 | 2.22 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €9.54 Million | € 5.96 Million | € 15.11 Million |
Biofrontera AG - Advanced Valuation Insights
This section examines the relationship between Biofrontera AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.07 |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | -3.5% |
| Total Assets | €29.65 Million |
| Market Capitalization | $3.73 Million USD |
Valuation Analysis
Below Book Valuation: The market values Biofrontera AG's assets below their book value (0.13 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Biofrontera AG's assets decreased by 3.5% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Biofrontera AG (2009–2024)
The table below shows the annual total assets of Biofrontera AG from 2009 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €29.65 Million | -3.51% |
| 2023-12-31 | €30.73 Million | -6.09% |
| 2022-12-31 | €32.73 Million | -57.01% |
| 2021-12-31 | €76.13 Million | +35.00% |
| 2020-12-31 | €56.39 Million | -3.38% |
| 2019-12-31 | €58.36 Million | +49.14% |
| 2018-12-31 | €39.13 Million | +97.16% |
| 2017-12-31 | €19.85 Million | -16.88% |
| 2016-12-31 | €23.88 Million | +151.41% |
| 2015-12-31 | €9.50 Million | -32.21% |
| 2014-12-31 | €14.01 Million | +45.38% |
| 2013-12-31 | €9.64 Million | +6.66% |
| 2012-12-31 | €9.04 Million | +58.59% |
| 2011-12-31 | €5.70 Million | +121.99% |
| 2010-12-31 | €2.57 Million | -23.75% |
| 2009-12-31 | €3.37 Million | -- |